Capricor Therapeutics
CAPR
21 hedge funds and large institutions have $3.01M invested in Capricor Therapeutics in 2017 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 4 increasing their positions, 4 reducing their positions, and 2 closing their positions.
250% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 2
17% more capital invested
Capital invested by funds: $2.57M → $3.01M (+$446K)
5% more funds holding
Funds holding: 20 → 21 (+1)
0% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 4
0.03% less ownership
Funds ownership: 0.45% → 0.42% (-0.03%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$171K |
| 2 |
AA
Apriem Advisors
Irvine,
California
|
+$139K |
| 3 |
VKH
Virtu KCG Holdings
New York
|
+$74.1K |
| 4 |
BlackRock
New York
|
+$53.3K |
| 5 |
Northern Trust
Chicago,
Illinois
|
+$47.4K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
-$373K |
| 2 |
Brown Advisory
Baltimore,
Maryland
|
-$189K |
| 3 |
Goldman Sachs
New York
|
-$49.3K |
| 4 |
Morgan Stanley
New York
|
-$41.6K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$38K |
CAPR Hedge Fund Activity: Q1 2017 in Review
21 of the 4,034 institutional investors tracked by Wall St. Rank reported a position in Capricor Therapeutics (CAPR) for Q1 2017, worth a combined $3.01M — up 17% from $2.57M a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new CAPR positions and 2 closed out — a net gain of 5 holders — while 4 added to existing stakes and 4 trimmed.
The largest buyer was Jacobs Levy Equity Management, opening a new position worth an estimated $171K. The largest seller was Sabby Management, cutting an estimated $373K.
- 21 institutional investors held Capricor Therapeutics (CAPR) as of Q1 2017, up from 20 in Q4 2016.
- Funds reported $3.01M of Capricor Therapeutics stock for Q1 2017, up 17% quarter-over-quarter.
- 7 funds opened new Capricor Therapeutics positions in Q1 2017 and 2 closed out, a net change of +5 holders.
- The largest Capricor Therapeutics buyer in Q1 2017 was Jacobs Levy Equity Management, an estimated $171K added.
- The largest Capricor Therapeutics seller in Q1 2017 was Sabby Management, an estimated $373K sold.
Based on aggregated 13F filings for Q1 2017.